Details for New Drug Application (NDA): 213233
✉ Email this page to a colleague
NDA 213233 describes NICOTINE POLACRILEX, which is a drug marketed by Fertin Pharma, Ivax Sub Teva Pharms, L Perrigo Co, P And L, Perrigo R And D, Aurobindo Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Pld Acquisitions, and Ppi-dac, and is included in fifty NDAs. It is available from fifty-six suppliers. Additional details are available on the NICOTINE POLACRILEX profile page.
The generic ingredient in NICOTINE POLACRILEX is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
The generic ingredient in NICOTINE POLACRILEX is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
Summary for 213233
| Tradename: | NICOTINE POLACRILEX |
| Applicant: | Dr Reddys Labs Sa |
| Ingredient: | nicotine polacrilex |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213233
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NICOTINE POLACRILEX | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 213233 | ANDA | Dr. Reddy's Laboratories Inc. | 43598-488 | 43598-488-10 | 4 BOTTLE in 1 CARTON (43598-488-10) / 27 LOZENGE in 1 BOTTLE |
| NICOTINE POLACRILEX | nicotine polacrilex | TROCHE/LOZENGE;ORAL | 213233 | ANDA | Dr. Reddy's Laboratories Inc. | 43598-488 | 43598-488-12 | 5 BOTTLE in 1 CARTON (43598-488-12) / 24 LOZENGE in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TROCHE/LOZENGE;ORAL | Strength | EQ 2MG BASE | ||||
| Approval Date: | Aug 4, 2020 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TROCHE/LOZENGE;ORAL | Strength | EQ 4MG BASE | ||||
| Approval Date: | Aug 4, 2020 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
